Sector News

Merck KGaA on track to complete Sigma-Aldrich acquisition

September 28, 2015
Life sciences

(RTTNews.com) – German drug maker Merck KGaA said it is on track to complete the acquisition of life science company Sigma-Aldrich Corp. and is is the process of fulfilling antitrust commitments to the European Commission.

The acquisition is expected to close within the next two months. Merck in August had forecast to complete the transaction in the third quarter.

The planned acquisition of Sigma-Aldrich for about $17 billion or 13.1 billion euros was announced in September 2014.

Merck said negotiations with potential buyers are in the final stage to sell parts of Sigma-Aldrich’s solvents and inorganics business. This was a condition set for obtaining European Commission approval. Merck on August 11 announced that it had obtained all other necessary antitrust approvals.

Merck added that once a binding agreement has been signed, the European Commission needs to approve the buyer before Merck can proceed with the completion of the Sigma-Aldrich acquisition.

Sigma-Aldrich shareholders approved the merger with Merck in December 2014. Merck has also completed its capital markets activities to finance the transaction with the placement of a 2.1 billion euro bond at the end of August.

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”